Targeted biodegradable rna-guided nanoparticles for organ-specific mrna delivery
A novel approach using PBAE-based nanoparticles coupled with targeting ligands via click chemistry for organ-specific mRNA delivery to the brain, lungs, spleen, and lymph nodes, enhancing uptake and minimizing off-target effects.
Overview
The innovative solution offered is the development of targeted biodegradable RNA-guided nanoparticles for organ-specific mRNA delivery. This technology utilizes PBAE-based polymers, coupled with specific targeting ligands through click chemistry, to achieve precise delivery of mRNA therapeutics to specific organs. The use of RGD peptides, vitronectin, and anti-CD4 antibodies allows for targeted delivery to glial cells in the brain, endothelial cells in the lung, and CD4+ T cells in the spleen and lymph nodes, respectively. This approach aims to enhance mRNA expression, improve therapeutic efficacy, and minimize off-target effects and toxicity.
Technical specifications
- PBAE-based polymers: Efficiently encapsulate mRNA and facilitate transfection across diverse cell types.
- Targeting ligands: RGD peptide, vitronectin, and anti-CD4 antibodies for targeting specific cells.
- Click chemistry: Used for coupling targeting ligands to polymers, ensuring precise ligand attachment.
- Optimization: Ligand density and formulation are optimized using Bayesian algorithms and microfluidic nanoparticle formulation to enhance delivery efficiency and organ tropism.
Technology readiness level
This technology is currently at TRL 4, indicating that it has been validated in a laboratory setting. Future validation steps include in vitro and in vivo testing to assess efficacy, targeting potential, and safety in relevant models.
About Ludwig-Maximilians Universität München
Ludwig‑Maximilians‑Universität München (LMU) is a large, comprehensive public research university in Munich with a global profile. For industry, its integration with a major university hospital enables clinical studies and translational pathways, while shared core facilities and co‑located laboratories support joint development and validation. LMU operates within Munich’s dense innovation ecosystem, linking corporate R&D to nearby national research institutes, a vibrant startup scene, and a strong talent pipeline. Research is backed by competitive German and European funding, including the German Research Foundation, the Federal Ministry of Education and Research, and EU programs. A dedicated technology transfer office streamlines IP strategy, licensing, and spin‑out formation for partners.
delivered to your inbox.